ライフサイエンスコーパス: DMF

1 DMF also modulated B-cell MHC II expression and reduced

2 DMF in vitro treatment also led to increased T cell apop

3 DMF induced cell death in primary patient-derived CD4(+)

4 DMF protected WT and Nrf2(-/-) mice equally well from de

5 DMF treatment delayed the growth of CTCL tumors and prev

6 DMF treatment is of particular promise in CTCL because D

7 DMF-induced cell death was linked specifically to NF-kap

8 t [Ni(II)(2)Dy(III)(2)L(4)(DMF)(6)] 2(OTf) 2(DMF) (1) promotes the domino reaction of furfural and am

9 diiron(II) complex, [Fe(2)(N-Et-HPTB)(NO)(2)(DMF)(2)](BF(4))(3) (2) with [{FeNO}(7)](2) formulation a

10 te based ultramicroporous MOF, 1 [Ni-(4PyC)2.DMF], that has the lowest PE for postcombustion CO2 capt

11 ormation of Co-BTTri (Co3[(Co4Cl)3(BTTri)8]2.DMF), a sodalite-type metal-organic framework.

12 framework Co-BDTriP (Co3[(Co4Cl)3(BDTriP)8]2.DMF; H3BDTriP = 5,5'-(5-(1H-pyrazol-4-yl)-1,3-phenylene)

13 rganic sodium ion electrolyte NaClO4 (DMF)3 (DMF=dimethylformamide) is described.

14 rmal crystallisation of a new MOF [Yb2(BDC)3(DMF)2]H2O (BDC=benzene-1,4-dicarboxylate and DMF=N,N-dim

15 o N-alkyl and N-acyl analogues (RX, NaHCO(3)/DMF/100 degrees C) in high overall yields.

16 bimetallic catalyst [Ni(II)(2)Dy(III)(2)L(4)(DMF)(6)] 2(OTf) 2(DMF) (1) promotes the domino reaction

17 emiconductors, [Fe(tpma)(xbim)](X)(TCNQ)(1.5)DMF (X=ClO4(-) or BF4(-); tpma=tris(2-pyridylmethyl)amin

18 o the fuel precursor 2,5-dimethyl furan (2,5-DMF).

19 Upon soaking in a DMF solution of Cp2Co, the compound undergoes a single-c

20 he optimum configuration is implemented on a DMF platform with an interdigitated capacitive biosensor

21 face features that have been integrated on a DMF platform: a reagent delivery system and a thermal co

22 hyl acetate, acetone, alcohol, acetonitrile, DMF, and DMSO, identify complex solvent systems, as well

23 In addition, DMF abrogated TGFbeta/Akt1 mediated inhibitory phosphory

24 In addition, DMF induced increased cell death in primary CTCL tumors

25 In addition, DMF inhibits cell proliferation and significantly impair

26 f the TU-metal chloride complex formed after DMF evaporation is critical to prevent volatilization of

27 ory Th2 subset (CCR3(+)) was increased after DMF treatment.

28 re collected at baseline and 12 months after DMF.

29 at baseline, and 1, 3, 6 and 12 months after DMF.

30 Although DMF did not eliminate the possibility of disease reactiv

31 and two transformation products of amitraz (DMF and DMPF), were quantified at higher levels in wax a

32 Combined treatment with ABT-199 and DMF caused synergistic cell death specifically in CTCL c

33 s in vivo, we performed combined ABT-199 and DMF treatment in a xenograft mouse model for CTCL.

34 DMF)2]H2O (BDC=benzene-1,4-dicarboxylate and DMF=N,N-dimethylformamide) under solvothermal conditions

35 examined and compared the effects of EP and DMF on MS-relevant activity/functions of T cells, macrop

36 ere also found for DMF, implying that EP and DMF share common targets and mechanisms of action.

37 loromethyl (1R,2S,5R)-(-)-menthyl ether, and DMF are used.

38 The inhibitory effect of 4-OI and DMF extends to the replication of several other pathogen

39 In conclusion, NRF2 agonists 4-OI and DMF induce a distinct IFN-independent antiviral program

40 In addition, 4-OI and DMF limit host inflammatory responses to SARS-CoV2 infec

41 ploying K2CO3 as a base in refluxing THF and DMF at 80 degrees C, respectively, delivers 2-aroylbenzo

42 PY to the chlorin moiety in both toluene and DMF and exhibits intense fluorescence of chlorin upon ex

43 toward different proton (4-nitrophenol and [DMF.H(+)](CF3SO3(-))) (DMF = dimethyl-formamide) or elec

44 1,3,5-(4-formylphenyl)-benzene in anhydrous DMF afforded porous BILP-15 (448 m(2) g(-1)) and BILP-16

45 and occurs at ambient temperature in aqueous DMF in an undivided cell open to air.

46 on experiments using polar solvents, such as DMF, no "mixed" products possessing structurally differe

47 we present a free-standing, fully automated DMF platform for immunoassay.

48 ent is of particular promise in CTCL because DMF is already in successful clinical use in the treatme

49 number of relapses and MRI parameters before DMF treatment were good predictors of disease activity d

50 on between Li(+) and the oxygen atom of both DMF and DMA that increases the extent of positive charge

51 Buffered DMF:DMF(H)(+) mixtures afforded an increase in the catal

52 re greater than those easily accommodated by DMF devices and contain analytes of interest at low conc

53 The protection afforded by DMF is mediated in part through inhibiting oxidative str

54 ifying enzyme, was significantly enhanced by DMF administration in kidney.

55 ur understanding of the proteins modified by DMF in human immune cells and the functional consequence

56 itially coordinated to Yb(3+) is replaced by DMF as the reaction progresses.

57 hione (GSH) abrogated ULBP2/5 upregulated by DMF.

58 n (4-nitrophenol and [DMF.H(+)](CF3SO3(-))) (DMF = dimethyl-formamide) or electron (decamethylferroce

59 As described herein, DMF-IP and P-CLIP-DMF-IP are rapid, automated, and multiplexed methods tha

60 in the compound (K[222-crypt])4 [Sn14 Ni(CO)]DMF.

61 ced in solvent of high dielectric constants (DMF), most likely by photoinduced electron transfer.

62 Coumaphos, DMF and DMPF were detected in honey in the range 6-36 ug

63 20 mg/kg per day intraperitoneally) or CsA + DMF (n = 7, 50 mg/kg per day orally) for 28 days.

64 creatinine (CsA 0.79 +/- 0.02 mg/dL vs CsA + DMF 0.62 +/- 0.04 mg/dL, P = 0.001) and urea (CsA 66.9 +

65 1) and urea (CsA 66.9 +/- 0.4 mg/dL vs CsA + DMF 53.3 +/- 2.6 mg/dl, P < 0.0001) levels, as well as i

66 nzimidazolyl))-2-hydroxy-1,3-diaminopropane; DMF = dimethylformamide) with [Fe(II){FeNO}(7)] formulat

67 agent, N,N-dimethylformamide dimethylacetal (DMF-DMA) and tetramethylammonium hydroxide (TMAH) as met

68 ormamidine (DMPF) and 2,4-dimethylformamide (DMF) into 2,4-dimethylaniline (DMA), directly from QuECh

69 thin films processed from dimethylformamide (DMF)-based solutions to which either no additive, dimeth

70 as synthesized by heating dimethylformamide (DMF) solution of the known Ni-centered and Ni(CO)-capped

71 h ferrocenoyl chloride in dimethylformamide (DMF), a regioselective acylation occurred.

72 In dimethylformamide (DMF), a solvent that disrupts hydrogen bonds, the ReDAC/

73 entially binds with NR in dimethylformamide (DMF)/water (1:1) solution over other cations such as Fe(

74 duction of formic acid in dimethylformamide (DMF)/water mixtures (Faradaic efficiency of 90 +/- 10%)

75 )benzene (H3BTTri) in N,N-dimethylformamide (DMF) and methanol leads to the formation of Co-BTTri (Co

76 adical (CumO(*)) with N,N-dimethylformamide (DMF) and N,N-dimethylacetamide (DMA) was studied by lase

77 at the combination of N,N-dimethylformamide (DMF) and TU has the remarkable ability to form intermedi

78 ulfurizer, Fe(II) and N,N-dimethylformamide (DMF) are introduced to Fe(III)-IL to construct a new non

79 loromethane (DCM) and N,N-dimethylformamide (DMF) as solvents) and relies on the utilization of the g

80 rollable synthesis of N,N-dimethylformamide (DMF) from dimethylamine and CO(2)/H(2) via blocking reac

81 ction is performed in N,N-dimethylformamide (DMF) in a continuous membrane reactor which retains the

82 in the gas phase, in N,N-dimethylformamide (DMF) solution, and in DMF solution in the presence of te

83 unknown breakdown of N,N-dimethylformamide (DMF) to formaldehyde at high temperature under mildly ac

84 hylacetamide (DMA) or N,N-dimethylformamide (DMF) was used to improve the separation selectivity.

85 ination of CO2(*-) in N,N-dimethylformamide (DMF) with the tip generation/substrate collection (TG/SC

86 ylacetamide (DMA) and N,N-dimethylformamide (DMF), as the background electrolyte (BGE) to improve the

87 from the C-H bonds of N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-formylpyrrolidine (

88 st molecules, such as N,N-dimethylformamide (DMF).

89 ts is possible using only dimethylformamide (DMF) and tetrabromomethane (CBr4) in the bromination of

90 ng a cooperative solvent, dimethylformamide (DMF), to synthesize core/shell architectured gold-phosph

91 solution casting of their dimethylformamide (DMF) solutions under ambient conditions.

92 e by replacing water with dimethylformamide (DMF) as the solvent during the synthesis.

93 When using dimethylformamidium, DMF(H)(+), the mechanism of H2 formation by 1 changes fr

94 and chronic treatment with dimethylfumarate (DMF) and BHB reduced the tactile allodynia.

95 DISCUSSION: DMF appeared generally safe and no carryover PML among i

96 he addition of trifluoroethanol (TFE), DMSO, DMF and acetone, uniform fiber-like nanoparticles from P

97 e in preventing the collapse of pores during DMF evaporation.

98 s Dy2(INO)4(NO3)22 solvent (solvent=DMF (Dy2-DMF), CH3CN (Dy2-CH3CN)), thereby switching the effectiv

99 urements) between a negligible value for Dy2-DMF and 76 cm(-1) for Dy2-CH3CN.

100 supporting the notion that the electrophile, DMF, acts via covalent modification.

101 otocols, showing that such a system enhances DMF performance.

102 These results establish DMF as an NFkappaB inhibitor with anti-tumor activity th

103 ion represents an important step forward for DMF, further enhancing its utility for a wide range of a

104 Most of these effects were also found for DMF, implying that EP and DMF share common targets and m

105 tudies thus identify a proteomic hotspot for DMF action that constitutes a druggable protein-protein

106 se results reveal a new molecular target for DMF and show that a clinically approved drug inhibits M1

107 N,N-dimethyl formamide (DMF) is an extensively used organic solvent but is also

108 the block in K63 and/or M1 chain formation, DMF inhibits NFkappaB and ERK1/2 activation, resulting i

109 al (VLF) cortex and the dorsomedial frontal (DMF) cortex appear to control vocalizations.

110 Dimethyl fumarate (DMF) (BG-12, Tecfidera) is a fumaric acid ester (FAE) th

111 e by the therapeutic drug dimethyl fumarate (DMF) also promotes ULBP2/5 surface expression.

112 ice daily), or open-label dimethyl fumarate (DMF) as a reference.

113 We found that dimethyl fumarate (DMF) delivered to cells or endogenous fumarate reacts wi

114 We show here that dimethyl fumarate (DMF) dose-dependently induces mitochondrial biogenesis a

115 o explore the efficacy of dimethyl fumarate (DMF) in preventing disease reactivation after NTZ discon

116 d the clinically approved dimethyl fumarate (DMF) induce a cellular antiviral program that potently i

117 Dimethyl fumarate (DMF) is a prescribed treatment for multiple sclerosis an

118 Dimethyl Fumarate (DMF) is an FDA approved anti-oxidative and anti-inflamma

119 Dimethyl fumarate (DMF) is indicated for the treatment of relapsing multipl

120 the protective effects of dimethyl fumarate (DMF) on CsA-induced nephrotoxicity by enhancing the anti

121 vestigated the effects of dimethyl fumarate (DMF) on CTCL cells in vitro and in vivo.

122 Dimethyl fumarate (DMF) possesses anti-inflammatory properties and is appro

123 Dimethyl fumarate (DMF), a new drug for multiple sclerosis (MS) treatment,

124 need, we examined whether dimethyl fumarate (DMF), an anti-inflammatory drug already in clinical use

125 ng sulforaphane (SFN) and dimethyl fumarate (DMF), are unable to induce a similar response.

126 the CNS-penetrating drug dimethyl fumarate (DMF), decreased supernatant glutamate and neurotoxicity.

127 first-line oral treatment dimethyl fumarate (DMF), we examined dynamics of neurofilament light (NFL)

128 ic acid esters, including dimethyl fumarate (DMF, Tecfidera; Biogen, Cambridge, MA), have shown thera

129 Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the

130 have recently shown that dimethyl fumerate (DMF) inhibits NF-kappaB acting as a survival factor in C

131 As described herein, DMF-IP and P-CLIP-DMF-IP are rapid, automated, and multi

132 and contributes to our understanding of how DMF may act clinically to ameliorate pathological proces

133 However, DMF treatment in randomized controlled MS trials was ass

134 (O2CPh)(NO)2](BF4)2 (1a) and [Fe2(N-Et-HPTB)(DMF)2(NO)(OH)](BF4)3 (2a), are characterized by FTIR and

135 Fe(III/II)-IL/DMF can remove hydrogen sulfide and can be regenerated t

136 queous desulfurization system (Fe(III/II)-IL/DMF).

137 Importantly, DMF prevented bleomycin-induced skin fibrosis in mice.

138 In DMF the complex shows three well-behaved redox waves in

139 In DMF, O-alkylation is faster than retroaldol-aldol rearra

140 In DMF/water (1:1, v/v), the receptor 1 showed a selectivit

141 ce (pK(a) values ranging from 3.4 to 13.5 in DMF) and the applied potential.

142 bonate, and mesitylenic acid as additives in DMF solvent.

143 N,N-dimethylformamide (DMF) solution, and in DMF solution in the presence of tetramethylammonium ions

144 rylmethyl bromides using t-BuOK as a base in DMF, followed by Pd(0)-mediated intramolecular Heck coup

145 the hydrolytic cleavage of the amide bond in DMF.

146 -free alkylation with methyl bromoacetate in DMF, saponification, and cyclization with acetic anhydri

147 ng reductive elimination at 140 degrees C in DMF to afford a beta-lactam product.

148 conditions examined (up to 140 degrees C in DMF).

149 r solvothermal treatment at 200 degrees C in DMF.

150 ransfer and TU to stabilize metal cations in DMF.

151 using Selectfluor in the presence of CsF in DMF at room temperature for 15-60 min provided beta-keto

152 ctivity for Br-capped acrylate chain ends in DMF, and moderate activity toward C-F bonds at room temp

153 s with the treatment with sodium ethoxide in DMF at room temperature provided highly substituted trie

154 catalyzes electro-assisted H(2) evolution in DMF with distinct mechanisms depending on the strength o

155 n depending on the solvent applied (e.g., in DMF ranging from 0.25 to 0.53).

156 ions are observed under microwave heating in DMF.

157 tion of benzyl bromide and sodium hydride in DMF can lead to the formation of an amine side product,

158 ar Heck coupling in the presence of K2CO3 in DMF at 80-140 degrees C.

159 ce were similar for patients with lesions in DMF or mOFC/vmPFC, compared with Controls.

160 perties, both thermotropic and lyotropic (in DMF) mesophases were observed in one of metallacycles, i

161 %) at moderate overpotentials (500-700 mV in DMF measured at the middle of the catalytic wave).

162 quinolizinium) in CH3CN to 507 and 553 nm in DMF, respectively.

163 the antiinflammatory contribution of Nrf2 in DMF treatment of the MS model, experimental autoimmune e

164 7-expressing CD4(+) T cells were observed in DMF-treated patients.

165 of dioxygen catalyzed by iron porphyrins in DMF as an example, decreasing [HA] 10-fold lowers etaeff

166 step single-pot synthesis occurs smoothly in DMF at rt.

167 her simple arenes in the presence of TBAF in DMF without the necessity of adding any ligands or addit

168 ) are much larger in apolar solvents than in DMF.

169 by iron(tetramesitylporphyrin) (Fe(TMP)) in DMF.

170 air-stable Ni(II) precatalysts were used in DMF under CF lamp irradiation; however, O2 was not requi

171 for fumarate-based therapeutics that include DMF, for the treatment of multiple sclerosis.

172 ated with the integration of biosensors into DMF: (1) complete removal of the droplet containing the

173 ngth was modulated from weak to strong (L' = DMF, MeCN, CN).

174 itu amine functionalized TMU-60 [Zn(OBA)(L*).DMF] has the potential of converting to a conductor due

175 2 (L3)(H2 O)2 ]n (NJU-Bai 42), and [Cu2 (L4)(DMF)2 ]n (NJU-Bai 43) were prepared and we observed that

176 y provides Class II evidence that first-line DMF reduces NFL in both blood and CSF after 6 months and

177 Mean DMF-T was significantly higher in patients with RA (19.3

178 Mechanistically, DMF prevents p65 nuclear translocation and attenuates it

179 h different polarities (i.e., toluene, MeOH, DMF, and DMSO).

180 esidues of amitraz or its other metabolites, DMF and DMA, were extracted using the QuEChERS method.

181 high-throughput screening (HTS) methodology, DMF and NaHCO3 were rapidly identified as the most effec

182 It consists of a digital microfluidic (DMF) diluter chip, an actuation element, a detector elem

183 be positioned between digital microfluidics (DMF) addressing each droplet individually using 2D array

184 Digital microfluidics (DMF) is a platform that enables highly reconfigurable an

185 Digital microfluidics (DMF) is a powerful technique for simple and precise mani

186 Digital microfluidics (DMF) represents an alternative to the conventional micro

187 e in-line coupling of digital microfluidics (DMF) with HPLC-MS, using a custom, 3D-printed manifold a

188 methodology, based on digital microfluidics (DMF), for rapid determination of individual alterations

189 pulation mechanism in digital microfluidics (DMF), where droplets can be actuated over a (super)hydro

190 on of biosensors into digital microfluidics (DMF).

191 tegration of ECL with digital microfluidics (DMF).

192 ein G, manipulated by digital microfluidics (DMF).

193 agnetic particles and digital microfluidics (DMF-IP).

194 solid-organic sodium ion electrolyte NaClO4 (DMF)3 (DMF=dimethylformamide) is described.

195 Pressed pellets of microcrystalline NaClO4 (DMF)3 exhibit a conductivity of 3x10(-4) S cm(-1) at roo

196 The crystal structure of NaClO4 (DMF)3 reveals parallel channels of Na(+) and ClO4(-) ion

197 on cooling, it resolidifies as solid NaClO4 (DMF)3 , permitting melt casting of the electrolyte into

198 yl diiron(II) complex, [Fe(2)(N-Et-HPTB)(NO)(DMF)(3)](BF(4))(3) (1) (N-Et-HPTB is the anion of N,N,N'

199 osyl diiron(II) complex, [Fe2(N-Et-HPTB)(NO)(DMF)3](BF4)3 (2).

200 uggest that the antiinflammatory activity of DMF in treatment of MS patients may occur through altern

201 teine 38 being essential for the activity of DMF.

202 The addition of DMF in Fe(III/II)-IL does not change the structure of Fe

203 Administration of DMF has a protective potential against CsA nephrotoxicit

204 In mice, the administration of DMF protects against lipopolysaccharide shock and allevi

205 Dimethyl succinate, the inactive analog of DMF that lacks the electrophilic double bond of fumarate

206 shelf agent, appears to be a redox analog of DMF, but its immunomodulatory properties have not been p

207 One of the major benefits of DMF is that fluid motion and control is achieved without

208 The automation component of DMF have pushed the barriers of this "lab-on-chip" techn

209 ion energy barriers during the conversion of DMF to N(CH(3))(3).

210 Coordination of DMF to the [((H)L)2Fe6] core leads to weaker Fe-Fe inter

211 The beneficial effect of DMF treatment in Nrf2(-/-) and WT mice was accompanied b

212 es a mechanism of the antifibrotic effect of DMF via inhibition of Akt1/GSK3beta/TAZ/YAP signaling an

213 his study was to assess the effectiveness of DMF as a therapy for PAH using patient-derived cells and

214 Our findings indicate that effects of DMF are facilitated by inhibiting pro-inflammatory NFkap

215 t HCA(2) mediates the therapeutic effects of DMF in EAE.

216 al results demonstrate beneficial effects of DMF on key molecular pathways contributing to PAH, and s

217 AP recapitulated the antifibrotic effects of DMF.

218 The electrophilicity of DMF suggests that its immunosuppressive activity is rela

219 o evidence of disease activity at the end of DMF treatment.

220 The flexibility of DMF is compromised when devices are permanently modified

221 A unique hallmark of DMF is its "flexibility": a generic device design can be

222 thways of further catalytic hydrogenation of DMF to N(CH(3))(3).

223 To study the impact of DMF in vivo, we developed 2 CTCL xenograft mouse models

224 fumarate (MMF), the bioactive metabolite of DMF, which can stabilize NRF2 and induce antioxidant gen

225 After 12 months of DMF treatment, NFL concentration decreased by 73%, 69% a

226 fabricated into the ITO-coated top plates of DMF devices, allowing for the generation of light from e

227 ing the automated sample processing power of DMF with the resolving and analytical capacity of HPLC-M

228 nthesized and used a novel chemical probe of DMF by incorporating an alkyne functionality and found t

229 Upon removal of DMF and H2O solvent molecules, the compound undergoes a

230 help to evaluate the efficacy and safety of DMF treatment.

231 nase IRAK4 as a principal cellular target of DMF.

232 This study supports the use of DMF as a treatment for SSc dermal fibrosis.

233 drug, our findings support a broader use of DMF in treatment of cancers and inflammatory conditions.

234 2 years of NTZ treatment and the 2 years of DMF were collected.

235 iron(II, III) complex, [Fe(2)(N-Et-HPTB)(OH)(DMF)(3)](BF(4))(3) (3).

236 ondrial gene expression is more dependent on DMF's target Nrf2 than hydroxycarboxylic acid receptor 2

237 luidic and temperature control integrated on DMF platforms.

238 Addition of DMA or DMF to the BGE impacts separation selectivity through di

239 olvent such as methanol, aqueous ethanol, or DMF or in biphasic mixtures that use acetonitrile.

240 Following oral DMF administration, central nervous system (CNS) tissue

241 Our observations that oral DMF treatment promoted immune modulation and provided eq

242 -55) for EAE induction and treated with oral DMF or vehicle daily.

243 ofluidics and embedded sensors: "plug-n-play DMF" (PnP-DMF).

244 and embedded sensors: "plug-n-play DMF" (PnP-DMF).

245 is paper provides "proof of concept" for PnP-DMF using commercial biosensors for glucose and beta-ket

246 In PnP-DMF, devices are designed to allow for rapid and seamles

247 sented here highlight the versatility of PnP-DMF, illustrating how it may be useful for a wide range

248 on going from nonpolar toluene to more polar DMF.

249 ere), mOFC/vmPFC, or dorsomedial prefrontal (DMF), and a comparison group of healthy age- and educati

250 ermeable thiol N-acetyl l-cysteine, reverses DMF inhibition of the NFkappaB pathway, supporting the n

251 ed free energy of 5.9 kcal/mol, in solution (DMF via C-PCM approach).

252 the phases Dy2(INO)4(NO3)22 solvent (solvent=DMF (Dy2-DMF), CH3CN (Dy2-CH3CN)), thereby switching the

253 show that DMFase from Paracoccus sp. strain DMF is a halophilic and thermostable enzyme comprising a

254 In summary, DMF treatment represents a remarkable therapeutic option

255 decayed, missing, and/or filled adult teeth [DMF-T] index); 2) gingival inflammation (papillary bleed

256 We find that DMF inhibits pro-inflammatory cytokine production in res

257 We found that DMF blocks the profibrotic effects of transforming growt

258 ating an alkyne functionality and found that DMF covalently modifies p65, with cysteine 38 being esse

259 We found that DMF effectively blocks NFkappaB activity in multiple bre

260 Mechanistically, we found that DMF treatment reduced nuclear localization of transcript

261 Given that DMF is an approved human therapeutic drug, our findings

262 ndent mammosphere formation, indicating that DMF has anti-cancer stem cell properties.

263 The observation that DMF stimulates mitochondrial biogenesis, gene expression

264 We propose that DMF-ECL represents a valuable new tool in the microfluid

265 In this study, we report that DMF inhibits human plasmacytoid dendritic cell function

266 We show that DMF blocks IRAK4-MyD88 interactions and IRAK4-mediated c

267 Instead we show that DMF can inhibit the E2 conjugating enzymes involved in K

268 We show that DMF treatment is effective in reversing hemodynamic chan

269 We further showed that DMF significantly diminished nuclear TAZ/YAP localizatio

270 Our results suggest that DMF acts on specific memory and effector T cell subsets

271 The DMF cotreatment ameliorated CsA-induced renal dysfunctio

272 imal geometry of the sensing surface and the DMF platform providing successful removal of the target

273 During the DMF phase, among the 39 patients, one or more relapses o

274 g twice-daily group, and 4.78+/-22.05 in the DMF group.

275 nib 75-mg twice-daily group, and 0.20 in the DMF group.

276 nto account the overall configuration of the DMF platform.

277 Finally, we demonstrate the ability of the DMF-TU molecular ink chemistry to lead to high-photovolt

278 tion in microscale volumes (5-15 muL) on the DMF device itself.

279 ical and radiological activity preceding the DMF treatment might be used as a prognostic marker of th

280 roheater array modularly integrated with the DMF platform.

281 Thus, DMF induces mitochondrial biogenesis primarily through i

282 s applicable to all biosensors integrated to DMF.

283 high risk of PML, were switched from NTZ to DMF and underwent neurological and 3T MRI monitoring for

284 ges are (1) delivering biological samples to DMF devices and (2) accurately controlling temperatures

285 pression of ULBP2/5 and were unresponsive to DMF treatment, suggesting that the fumarate-stimulating

286 The world-to-DMF system is designed for flexibility in accommodating

287 domonas, and Alcaligenes have evolved to use DMF as a sole carbon and nitrogen source for growth via

288 -methylation of ketones via enaminones using DMF dimethyl acetal as carbon source.

289 s of the various areas that comprise the VLF-DMF network in learning rule-based cognitive selections

290 that the basic function expressed by the VLF-DMF network is to exert cognitive control of orofacial a

291 er solvothermal conditions, from mixed water/DMF solvent.

292 e in a counter-current membrane system where DMF is continuously replaced by ethanol.

293 To determine whether DMF interacts directly with p65, we synthesized and used

294 se models, prompting us to determine whether DMF is effective as a treatment for SSc dermal fibrosis.

295 With DMF, a solvent-induced change in HAT selectivity was obs

296 sed and the CD4/CD8 ratio was increased with DMF treatment.

297 n at -75 degrees C followed by reaction with DMF gave 2-formyl-4-chloro-3-fluoropyridine 10 regiosele

298 T cell activation was reduced with DMF treatment, especially among effector memory T cells

299 nally, we showed that chronic treatment with DMF reduced the firing of the ON cells (cells responding

300 rs of disease activity during treatment with DMF.